339 related articles for article (PubMed ID: 22580756)
1. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.
Pfaller MA; Woosley LN; Messer SA; Jones RN; Castanheira M
Mycopathologia; 2012 Oct; 174(4):259-71. PubMed ID: 22580756
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
6. [Changing Trends in Isolation Frequencies and Species of Clinical Fungal Strains: What Do the 12-years (2008-2019) Mycology Laboratory Data Tell About?].
Gülmez D; Sığ AK; Akar N; Duyan S; Arıkan Akdağlı S
Mikrobiyol Bul; 2021 Jan; 55(1):53-66. PubMed ID: 33590981
[TBL] [Abstract][Full Text] [Related]
7. Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4+T-cell counts.
Roohani AH; Fatima N; Shameem M; Khan HM; Khan PA; Akhtar A
Indian J Med Microbiol; 2018; 36(3):408-415. PubMed ID: 30429396
[TBL] [Abstract][Full Text] [Related]
8. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
Castanheira M; Messer SA; Rhomberg PR; Pfaller MA
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):200-4. PubMed ID: 27061369
[TBL] [Abstract][Full Text] [Related]
10. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
12. Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species.
Melhem MS; Bertoletti A; Lucca HR; Silva RB; Meneghin FA; Szeszs MW
Braz J Microbiol; 2013 Dec; 44(4):1257-66. PubMed ID: 24688520
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
Wang H; Xiao M; Chen SC; Kong F; Sun ZY; Liao K; Lu J; Shao HF; Yan Y; Fan H; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Xu YC
J Clin Microbiol; 2012 Dec; 50(12):3952-9. PubMed ID: 23035204
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of isavuconazole against clinically isolated yeasts from Chile.
Álvarez Duarte E; Salas V
Braz J Microbiol; 2020 Dec; 51(4):1801-1805. PubMed ID: 32638272
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of common commercial systems for the identification of yeast isolates in microbiology laboratories: a multicenter study].
Karabıçak N; Uludağ Altun H; Karatuna O; Hazırolan G; Aksu N; Adiloğlu A; Akyar I
Mikrobiyol Bul; 2015 Apr; 49(2):210-20. PubMed ID: 26167821
[TBL] [Abstract][Full Text] [Related]
16. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Pfaller MA; Messer SA; Jones RN; Castanheira M
J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
[TBL] [Abstract][Full Text] [Related]
19. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.
Rambach G; Oberhauser H; Speth C; Lass-Flörl C
Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
